CCR4 and peripheral T-cell lymphoma, not otherwise specified: Mogamulizumab was subsequently approved for relapsed or refractory CCR4-positive peripheral T-cell lymphoma, relapsed or refractory cutaneous T-cell lymphoma, and chemotherapy-untreated CCR4-positive adult T-cell leukemia/lymphoma, combined with other antineoplastics.